Novo Nordisk beats first-quarter profit forecasts and raises full-year guidance
Updated
Updated · Reuters · May 6
Novo Nordisk beats first-quarter profit forecasts and raises full-year guidance
15 articles · Updated · Reuters · May 6
Adjusted operating profit reached 32.86 billion Danish crowns versus 28.74 billion forecast, while Wegovy pill sales hit 2.26 billion crowns, nearly double expectations.
Shares rose 5.8% as the Danish drugmaker said first-quarter prescriptions reached 1.3 million and more than half of US Wegovy sales now come through lower-priced self-pay channels.
Novo is using the pill to regain ground on Eli Lilly after last year's margin pressure and now plans launches beyond the United States in the second half of 2026.
Could Novo Nordisk's oral Wegovy pill reshape global obesity care, or will fierce competition and regulatory hurdles limit its impact?
With patients rapidly adopting GLP-1 pills, how might this pharmaceutical boom transform food industries, healthcare systems, and long-term public health?